ABSTRACT Tuberculosis (TB) and multidrug-resistant tuberculosis (MDR-TB) remain a global health issue today. There exists an unmet need for a point-of-care TB diagnostic device that is accurate and suitable for use in resource-limited, high-burden settings. This study is the first demonstration of an isothermal DNA assay to identify MDR-TB, with future applications in a low-cost mobile phone diagnostic device. Using loop-mediated isothermal amplification, three primer signatures were identified to have high specificity, high sensitivity, and low limit of that a relatively high concentration of PNA clamp relative to DNA template is required for inhibition. In future work, PNA clamp design will be improved to increase inhibition of drugsusceptible MTB DNA reactions. Additionally, the effects of the clamps on drug-resistant MTB
INTRODUCTION
The bacterium Mycobacterium tuberculosis (MTB) causes tuberculosis (TB), the second leading cause of death due to infectious disease worldwide. In 2011, there were 9 million new TB cases and 1.4 million deaths due to TB. Moreover, multidrug-resistant tuberculosis (MDR-TB) constitutes 3.7% of new and 20% of previously treated TB cases globally. MDR-TB is characterized by resistance to rifampicin and isoniazid, two of the most powerful drugs used to treat drug-susceptible TB. Treatment regimens for MDR-TB generally last for 20 months, significantly longer than the 6-month treatment for drug-sensitive TB. 1 There remains an unmet need for a point-of-care TB diagnostic device that is suitable for use in settings with limited resources. We propose a device based on a mobile phone platform, which uses an isothermal nucleic acid amplification assay to identify drug-sensitive and drug-resistant TB.
The World Health Organization (WHO) has identified the continuing need for early TB case detection and effective diagnostic technologies. 2 In 2011, the global case detection rate for TB-the proportion of all cases that were diagnosed-was 66%. 1 The conventional method used for TB diagnosis is sputum smear microscopy, in which patient sputum samples are examined under the microscope for the presence of MTB. This detection method is limited in sensitivity, as only 28% of incident TB cases are determined to be smear positive. 3 Furthermore, the test does not identify between drug-sensitive and drug-resistant strains of bacteria.
Although the Xpert MTB/RIF assay was endorsed by WHO in 2010 and has been described as a landmark development in diagnostic technology, 4 it does not fulfill the requirements for a true point-of-care test. 4, 5 The assay uses real-time polymerase chain reaction analysis to detect the presence of MTB in processed sputum samples. Additionally, the reaction identifies rifampicin resistance as a surrogate indicator for MDR-TB. The objective of this study is to develop an isothermal DNA assay to detect MTB and drug-resistant MTB, for future application in low-cost point-of-care diagnostics. MTB identification will be achieved with loop-mediated isothermal amplification (LAMP). The technique employs a set of primers that create artificial stem-loops in amplified DNA and a DNA polymerase that exhibits strand-displacement activity. 6 The DNA amplification reaction will be visualized in real-time using a dsDNA-intercalating fluorescent dye.
To distinguish between drug-susceptible and drug-resistant MTB, peptide nucleic acid (PNA) clamps will be added to the LAMP reactions. PNA is a synthetic polymer with an amide backbone and nitrogenous bases, and can be designed to match target DNA sequences. A PNA clamp bound to complementary DNA has a higher melting temperature than that of the corresponding dsDNA duplex; the strong binding of PNA to DNA has been shown to inhibit polymerase displacement activity and DNA amplification. A single base mismatch between the PNA-DNA hybrid causes destabilization, allowing the amplification reaction to proceed. 7 It is expected that PNA clamps designed to bind to wildtype drug-susceptible MTB DNA will inhibition LAMP reactions; because they will not bind as strongly to mutant drug-resistant MTB DNA, amplification will proceed without inhibition.
The specific goals of this study are: 1) to identify primer signatures that amplify MTB DNA with high sensitivity, high speed, and low limit of detection; 2) to characterize the primers' specificity-their ability to distinguish between MTB and genetic near-neighbors (nontuberculosis mycobacteria, or NTM); and 3) to identify PNA clamps that inhibit amplification of In the initial screening process, each of the 5 primer signatures were tested against 4 different drug-susceptible MTB and 14 NTM DNA extracts. Each DNA extract (BEI, ATCC, and isolates from collaborators at UCSF) was tested in triplicate at 100pg/reaction. Primer signatures that performed well in the initial screening were further tested for limit of detection; the four MTB DNA extracts were tested at concentrations of 100pg, 10pg, 1pg, 100fg, and 10fg per reaction. Table 1 in the Appendix shows the mean amplification times for the initial screening of 5 primer sets against 4 MTB and 14 NTM DNA extracts. Primer sets 1, 2, and 5 showed sensitivity in amplifying MTB DNA. Threshold times for the four MTB DNA extracts ranged from 21 to 32 minutes for primer set 1, 31 to 48 minutes for primer set 2, and 14 to 21 minutes for primer set 5.
RESULTS
Out of these three primer sets, primer set 5 MTB reactions were the fastest to amplify and had the highest maximum fluorescence values (around 1000 RFU). In contrast, primer set 3 MTB reactions were slowest to amplify and had the lowest maximum fluorescence values (around 500 RFU). Primer sets 3 and 4 did not amplify all MTB DNA extracts, and were not further tested in limit of detection and PNA clamp studies.
Out of the three primer sets that amplified MTB DNA, primer set 5 also showed good specificity for MTB DNA. As shown in Figure 1 in the Appendix, amplification times for MTB DNA were lower than those for NTM DNA. Primer sets 1 and 2 also showed some degree of specificity in amplifying MTB DNA; most NTM strains had longer amplification times than Primer sets 1, 2, and 5 were tested for limit of detection with the 4 MTB DNA extracts.
Amplification times for the MTB 1 DNA extract are shown in Table 2 The factors that influence PNA clamp behavior have not been extensively studied.
Preliminary results from this study showed a direct relationship between clamp GC content and inhibition time; however, there is a need for further investigation regarding how best to design PNA clamps for applications in LAMP reactions.
The data in this study highlight a potential challenge in the use of PNA clamps in LAMP reactions to distinguish between drug-susceptible and drug-resistant MTB. Inhibition of LAMP reactions for drug-susceptible MTB DNA requires high concentrations of PNA clamp relative to DNA template. There must be a sufficient amount of PNA clamp in the reaction to bind with all of the DNA present; even a small number of DNA molecules without PNA clamps can be amplified and produce a positive reaction. This effect of potential amplification can be limited by using a clamp with high binding affinity; future work will focus on designing and testing clamps that more strongly inhibit drug-susceptible DNA reactions than the ones characterized in this study.
Lau 9
This study demonstrates the feasibility of a rapid, low-cost DNA amplification assay to detect drug-susceptible and drug-resistant TB. The isothermal reaction does not require expensive thermal cycling equipment, and the real-time fluorescence measurements can be optimized for the optics of a mobile phone. Because of these characteristics, the LAMP and PNA assays are suitable for application in a point-of-care diagnostic device. Table 4 . Average inhibition times (minutes) of four drug-susceptible MTB strains. All combinations of two primer signatures and two PNA clamps tested at 1pg DNA per reaction. 
